Isotretinoin in acne: how much and for how long?
DOI:
https://doi.org/10.66344/jpad.25.1.2015.14Abstract
No abstractReferences
Leyden JJ, Del Rosso JQ, Baum EW. The Use of isotretinoin in the treatment of acne vulgaris: Clinical considerations and future directions. J Clin Aesthet Dermatol. 2014;7 (Suppl):S5-S21.
Rademaker M. Isotretinoin: Dose, duration and relapse. What does 30 years of usage tell us? Aust J Dermatol. 2013;54:157-62.
Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol. 2010;76:7-13.
Plewig G, Dressel H, Pfleger M et al. Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne. J Dtsch Dermatol Ges. 2004;2:31-45.
Low dose isotretinoin for acne? Best Pract J;2013;56:16-7.
Thielitz A, Gollnick H. Isotretinoin. How should it be used? Hautarzt. 2013;64:263-8.
Blasiak RC, Stamey CR, Burkhart CN et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013;149:1392-8.
Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol. 2013;69:762-7.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
